Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Shattuck Labs (NASDAQ: STTK) granted inducement equity awards on Dec 10, 2025 to a newly hired non-executive officer under Nasdaq Listing Rule 5635(c)(4).
The awards are non-qualified stock options to purchase 206,000 shares at an exercise price of $3.23 per share, with a maximum term of 10 years. Vesting is 25% on Nov 17, 2026 and the remainder vests in equal monthly installments over the following 36 months. The awards were granted outside the Company’s 2020 Equity Incentive Plan but are generally subject to the same terms and were approved by the independent Compensation Committee.
Details
News Market Reaction – STTK
On Dec 16, the first trading day after this news, STTK closed 3.92% below the previous close.
Data tracked by StockTitan Argus for the Dec 16 session.
Key Figures
- Inducement options
- 206,000 shares
- Non-qualified stock options granted to a newly hired non-executive officer
- Exercise price
- $3.23 per share
- Strike price for inducement stock options
- Option term
- 10 years
- Maximum term of inducement stock options
- Initial vesting tranche
- 25%
- Portion of award vesting on November 17, 2026
- Remaining vesting period
- 36 months
- Remaining options vest monthly after November 17, 2026
- Grant Date
- December 10, 2025
- Date inducement equity awards were granted
- Current price
- $3.10
- Pre-news trading price on analysis date
- 52-week range
- $0.6922 – $3.38
- 52-week low and high before this news
Historical Context
-
Announced participation in multiple December 2025 investor conferences.
-
Reported Q3 2025 results and SL-325 progress with funding into 2029.
-
Disclosed participation in a Wedbush KOL and company panel post-UEGW.
-
Closed up to $103M private placement and refreshed Board of Directors.
-
IND for SL-325 became effective for IBD with Phase 1 trial plans.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
non-qualified stock options financial
exercise price financial
vesting financial
Nasdaq Listing Rule 5635(c)(4) regulatory
Equity Incentive Plan financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
AUSTIN, TX and DURHAM, NC, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that it has granted inducement equity awards on December 10, 2025 (the “Grant Date”) to a newly-hired non-executive officer.
The inducement awards consist of non-qualified stock options to purchase 206,000 shares of Shattuck’s common stock with an exercise price of
About Shattuck Labs, Inc.
Shattuck Labs, Inc. is a clinical-stage biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. The Company is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
Investor & Media Contact:
Andrew R. Neill
Chief Financial Officer
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.